Meta-analysis results of GLP1-RAs trials for stroke risk with different baseline characteristics across studies, those diabetic populations not at risk, or those not at risk for CKD or CVD are summarized in the Supplementary material (fixed and random effect models; Supplementary Figures S7, S8). This evidence concerns the gene GCG and chronic kidney disease.